secwatch.observer — SEC 8-K summary
======================================

Issuer:     Traws Pharma, Inc. (TRAW)
CIK:        0001130598
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001104659-23-060943
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Onconova Q1 net loss $5.8M; rigosertib achieves complete responses in RDEB-SCC
------------------------------------------------------------------------------

- Cash $34.2M as of March 31, 2023; expects runway into Q1 2024.
- Net loss $5.8M ($0.28/sh) vs $4.1M ($0.20/sh) in Q1 2022; R&D expenses doubled to $4.1M.
- First patient dosed in Phase 1/2a trial of narazaciclib plus letrozole in LGEEC; preliminary data expected Q4 2023.
- Both evaluable patients in rigosertib RDEB-SCC trial achieved complete cutaneous remissions; FDA Type B meeting requested.
- Entered collaboration with Pangea Biomed to identify biomarkers for rigosertib response.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130598/000110465923060943/0001104659-23-060943-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130598/000110465923060943/tm2315886d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-060943

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer